Senhwabio.com

Senhwabio.com has server used 61.219.164.24 (Taiwan) ping response time Hosted in Data Communication Business Group, Register Domain Names at Register.com, Inc.. This domain has been created 8 years, 174 days ago, remaining 190 days. You can check the 4 Websites and blacklist ip address on this server

Domain information

Registrar WHOIS Server: whois.register.com

Registrar URL: http://www.register.com     See All 141,293+

Creation Date: 2013-05-01 8 years, 174 days

Updated Date: 2021-04-01 205 days ago

Expiry Date: 2022-05-01 190 days left     See All

  Sign up for notifications near expiration

Registrar: Register.com, Inc.

Abuse Email: [email protected]

Abuse Phone: +1.8003337680

  Full details

Top 10 Hosting Providers

Registrar URLDomain CountsRegistrar NameAbuse Email
www.godaddy.com2,280,668GoDaddy.com, LLC[email protected]
www.tucows.com535,579Tucows Domains Inc.
networksolutions.com526,027Network Solutions, LLC[email protected]
www.namecheap.com333,839NameCheap, Inc.[email protected]
www.enom.com299,925eNom, LLC
www.publicdomainregistry.com294,948PDR Ltd. d/b/a PublicDomainRegistry.com[email protected]
www.whois.godaddy.com174,077GoDaddy.com, LLC[email protected]
www.fastdomain.com161,753FastDomain Inc.[email protected]
www.ionos.com159,2071&1 IONOS SE[email protected]
www.networksolutions.com149,653Network Solutions, LLC[email protected]

Full view & Download

Keywords Suggestions

Senhwa bio

Senhwa bioscience

Senhwa biosciences of taiwan

Senhwa biosciences san diego

( Please select at least 2 keywords )

See More:   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z  

Hosting Provider

NetName: HINET-NET

Organization: Data Communication Business Group,     See All 3,963+

Provider URL: Twnic.net.tw

Hostname: twshmg.senhwabio.com

IP Server: 61.219.164.24 Reg: , Updated: 2013-12-04T12:38:11Z

Blacklist: Check Backlist Status

Country: Taiwan

Address: Taipei, Taiwan, 100, TW

Latitude: 23.500000

Longitude: 121.000000

Name Server:

  • DNS101.REGISTER.COM
  • DNS102.REGISTER.COM

Abuse Email: [email protected]

Abuse Phone: +886 2 2322 3495

Top 10 Hosting Providers

Website URLDomain CountsOrganizationAbuse Email
Google.com681,421Google LLC[email protected]
Godaddy.com650,706GoDaddy.com, LLC[email protected]
Cloudflare.com637,900Cloudflare, Inc.[email protected]
Endurance.com488,827The Endurance International Group, Inc.[email protected]
Amazon.com439,891Amazon Technologies Inc.[email protected]
297,405Domain Name Services
Amazonaws.com287,121Amazon Technologies Inc.[email protected]
Liquidweb.com159,971Liquid Web, L.L.C[email protected]
Squarespace.com150,667Squarespace, Inc.[email protected]
Ripe.net128,362RIPE Network Coordination Centre[email protected]

Full view & Download

List of found email addresses

  1: [email protected]

Find Websites hosted

1: Senhwabio.com

2: Technobezz.com Changed to: 104.26.9.27

3: Home.bt.com Changed to: 68.142.68.29

4: Whatismyip.com Changed to: 104.27.195.88

At least 4 Sites on this server

Port Scanner (IP: 61.219.164.24)

Senhwa Biosciences Email Format Senhwabio.com Emails

  • Senhwa Biosciences Email Format
  • Senhwa Biosciences uses 2 email formats, with first last (ex
  • [email protected]) being used 71.7% of the time
  • Get Verified Emails for Senhwa Biosciences Employees
  • Senhwa Biosciences's Email Format

Rocketreach.co   DA: 14 PA: 49 MOZ Rank: 63

Home Senhwa Biosciences, Inc.

One Drug with Multi-target Therapy Senhwa’s Pidnarulex (CX-5461) has proven to be the next generation DDR (DNA Damage Response) drug, with the mechanism of synthetic lethality across multiple tumor types in patients with loss of function of tumor suppressor genes such as HRD (Homologous Recombination Deficiency) and beyond, and has great potential for patients who have developed …

Senhwabio.com   DA: 17 PA: 3 MOZ Rank: 21

Fcap John Soong's Email & Phone Senhwa Biosciences's

  • View Fcap's Contact Info (It's Free) Redirecting you to the search page
  • If you're not automatically redirected, please click here
  • Join in 5 seconds, no credit card required!

Rocketreach.co   DA: 14 PA: 25 MOZ Rank: 41

Company Profile Senhwa Biosciences, Inc.

  • Senhwa Biosciences, Inc was established in 2012 and aims to transform the model for new drug development by focusing on human efficacy
  • Senhwa believes that its dedication to science and rigorous processes will enable Senhwa to …

Senhwabio.com   DA: 17 PA: 6 MOZ Rank: 26

Ruby Wu's Email & Phone Senhwa Biosciences's Manager

  • Ruby Wu's Email Found 1 email: @senhwabio.com Preparing Ruby's profile… View Ruby's Email (It's Free) 5 free lookups per month
  • Redirecting you to the search page
  • If you're not automatically redirected, please

Rocketreach.co   DA: 14 PA: 22 MOZ Rank: 40

Yi-Hsuan Lai's Email & Phone Roche's Study Start Up

  • Yi-Hsuan Lai's Email Found 1 email: @senhwabio.com Preparing Yi-Hsuan's profile… View Yi-Hsuan's Email (It's Free) 5 free lookups per month
  • Redirecting you to the search page
  • If you're not automatically redirected, please

Rocketreach.co   DA: 14 PA: 27 MOZ Rank: 46

Senhwa Presents Positive Initial Data From

  • TAIPEI and SAN DIEGO, October, 20, 2021-- Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced the positive efficacy and safety results from an investigator-initiated, Phase 2 clinical trial of Silmitasertib in

Senhwabio.com   DA: 17 PA: 17 MOZ Rank: 40

Senhwa Announces First Patient Successfully

  • 10, 2021--Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a Phase 1b clinical study of Pidnarulex as a potential

Senhwabio.com   DA: 17 PA: 17 MOZ Rank: 41

Senhwa’s Silmitasertib Receives US FDA Fast

  • Senhwa’s Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma
  • 17, 2021 -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses

Senhwabio.com   DA: 17 PA: 17 MOZ Rank: 42

Senhwa Reports EIND Silmitasertib Treated Severe COVID-19

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, recently announced that a patient with severe COVID-19 demonstrated remarkable recovery after treatment with the Company's investigational drug, Silmitasertib.

Taiwantrade.com   DA: 19 PA: 50 MOZ Rank: 78

Senhwa Biosciences, Inc. LinkedIn

  • Senhwa Biosciences, Inc., a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the

Linkedin.com   DA: 16 PA: 27 MOZ Rank: 53

Senhwa Announces The First Patient Enrolled In An

Highlights: The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib.

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 79

2021 BIO-Asia Taiwan- LIVE Online Panel Discussion

本公司受邀參加2021 BIO-Asia Taiwan- LIVE Online Panel Discussion_ Pandemic Control After Vaccination

Youtube.com   DA: 15 PA: 6 MOZ Rank: 33

Senhwa Announces First Patient Successfully Dosed In Phase

  • 10, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focusing on …

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 81

Senhwa Signs Agreement With Taiwan's CDE For COVID-19

  • 14, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, Silmitasertib, has been included in Taiwan's Center for Drug Evaluation: "CDE can Help: COVID-19 Regulatory Consultation Program".

Chinamoneynetwork.com   DA: 25 PA: 50 MOZ Rank: 89

Intellasia East Asia News

  • 14, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, Silmitasertib, has been included in Taiwan's Center for Drug Evaluation: "CDE can Help: COVID-19 Regulatory Consultation Program".

Intellasia.net   DA: 18 PA: 50 MOZ Rank: 83

Senhwa Announces The First Patient Enrolled In An

  • (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 83

Ruby Wu: Business Profiles ZoomInfo.com

  • Find contact and company information for business people in our free business information database

Zoominfo.com   DA: 16 PA: 15 MOZ Rank: 48

Senhwa Announces Acceptance Of Early Positive COVID-19

  • /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 86

Senhwa Biosciences SENHWA BIOSCIENCES

  • 10509 Vista Sorrento Parkway, Suite 201, San Diego, CA 92121
  • Description: Senhwa Biosciences, Inc
  • (Senhwa) is a drug development company
  • It is engaged in development of small molecule drugs for treating newly validated targets in cancer pathways.

Bizstanding.com   DA: 15 PA: 22 MOZ Rank: 56

Joann Lo: Business Profiles ZoomInfo.com

  • Find contact and company information for business people in our free business information database

Zoominfo.com   DA: 16 PA: 16 MOZ Rank: 52

Intellasia East Asia News

  • 2020 /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study …

Intellasia.net   DA: 18 PA: 50 MOZ Rank: 89

Olga Titova: Business Profiles ZoomInfo.com

  • Find contact and company information for business people in our free business information database
  • This directory covers Olga Titova

Zoominfo.com   DA: 16 PA: 19 MOZ Rank: 57

Senhwa Biosciences – San Diego Biotechnology Network

[ October 19, 2021 ] Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights News [ October 19, 2021 ] Senior Principal Scientist, RNA Replicon Team Leader – Johnson & Johnson Family of …

Sdbn.org   DA: 8 PA: 50 MOZ Rank: 81

Senhwa Biosciences Receives US FDA 'Study May Proceed

  • 2020 /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study …

Biospace.com   DA: 16 PA: 50 MOZ Rank: 90

Senhwa Biosciences Receives US FDA 'Study May Proceed

  • 2020 /PRNewswire/ -- Senhwa Biosciences, Inc
  • (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study …

En.prnasia.com   DA: 14 PA: 50 MOZ Rank: 89

Senhwa Presents Positive Initial Data From Phase 2

2 days ago · Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 94

Senhwa Announces Acceptance Of Early Positive COVID-19

  • (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and …

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 94

Senhwa Signs Agreement With Taiwan's CDE For COVID-19

  • 13, 2021 /PRNewswire/ — Senhwa Biosciences, Inc
  • (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, Silmitasertib, has been included in Taiwan’s Center for Drug Evaluation: “CDE can Help: COVID-19 Regulatory Consultation Program”.

Forbesalert.com   DA: 15 PA: 50 MOZ Rank: 93

SENHWA BIOSCIENCES INC (6492.TWO) Stock Price, News, Quote

Find the latest SENHWA BIOSCIENCES INC (6492.TWO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Finance.yahoo.com   DA: 17 PA: 16 MOZ Rank: 62

Recently Analyzed

1: Cld-longueuil.ca 4 seconds ago

2: Senhwabio.com 1 seconds ago

3: Kuaimaoav.com 3 seconds ago

4: E-pneumatic.com 3 seconds ago

5: Getblogs.net 2 seconds ago

6: Aspenrxhealth.com 1 seconds ago

7: Tribarmanufacturing.com 0 seconds ago

8: Infanciayeducacion.com 1 seconds ago

9: Deluxe.ca 1 seconds ago

10: Askyvi.com 1 seconds ago

Tool Checker

Domain Expiry Date Updated

Expiry DateExpiry DateDomain ProviderHosting Provider
Askyvi.com 166 days leftName.com, Inc.Cloudflare, Inc.
Deluxe.ca9 years, 226 days leftTucows.com Co.Deluxe Corporation
Infanciayeducacion.com 182 days leftSoluciones Corporativas IP, SLDomain Name Services
Tribarmanufacturing.com 127 days leftNetwork Solutions, LLCYHC Corporation
Aspenrxhealth.com1 year, 148 days leftGoDaddy.com, LLCGoogle LLC
Getblogs.net 264 days leftNameCheap, Inc.Cloudflare, Inc.
E-pneumatic.com6 years, 34 days leftOVH sasDomain Name Services
Kuaimaoav.com 81 days leftGoDaddy.com, LLCDomain Name Services
Senhwabio.com 190 days leftRegister.com, Inc.Yuan-Jhen Info., Co., Ltd
Cld-longueuil.ca 114 days leftGo Daddy Domains Canada, IncA2 Hosting, Inc.

<< See All >>

.COM - 10,595,200+   .ORG - 1,117,549+   .EDU - 123,500+   .NET - 792,945+   .GOV - 30,232+   .US - 84,439+   .CA - 122,904+   .DE - 220,061+   .UK - 272,390+   .IT - 108,882+   .AU - 152,812+   .CO - 51,739+   .BIZ - 59,081+   .IO - 32,494+   .NL - 99,647+   .SG - 19,713+   .INFO - 81,589+   .IE - 26,934+   .ME - 25,076+   .FR - 98,576+   .EU - 61,372+   .RU - 165,043+   .PH - 9,511+   .INT - 1,166+   .IN - 87,021+   .ES - 38,035+   .CZ - 71,869+   .VN - 48,920+   .TV - 14,250+   .SITE - 9,829+   .RO - 37,484+   .PL - 44,520+   .PK - 10,373+   .MOBI - 4,464+   .LK - 5,507+   .CN - 66,137+   .CH - 66,914+   .AT - 31,992+  

Email Address Search | IP Address Blacklist Check | Hosting Providers | Domain Providers | Website Error Checker

© 2018 Site-Stats.org. All rights reserved. Email: [email protected]